Background. HA-1A is a human monoclonal IgM antibody that binds specifically to the lipid
A domain of endotoxin and prevents death in laboratory animals with gram-negative …

Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …

Background A recombinant, soluble fusion protein that is a dimer of an extracellular portion
of the human tumor necrosis factor (TNF) receptor and the Fc portion of IgG1 (TNFR:Fc) …

Objective. —To further define the safety and efficacy of recombinant human interleukin 1
receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. Study Design. —Randomized…

In an effort to decrease deaths from gram-negative bacteremia and endotoxin shock, we
treated bacteremic patients with human antiserum to endotoxin (lipopolysaccharide) core. …

Objective To determine the therapeutic efficacy and safety of recombinant human interleukin-1
receptor antagonist (rhIL-1ra) in the treatment of patients with severe sepsis. Design …

Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus
disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome …

The Ad26.COV2.S vaccine 1 , 2 – 3 has demonstrated clinical efficacy against symptomatic
COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing …

Background The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus
disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy …

Importance Control of the global COVID-19 pandemic will require the development and
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26…